PT  - JOURNAL ARTICLE
AU  - Moallemian, Soodeh
AU  - Salmon, Eric
AU  - Bahri, Mohamed Ali
AU  - Beliy, Nikita
AU  - Delhaye, Emma
AU  - Balteau, Evelyne
AU  - Degueldre, Christian
AU  - Phillips, Christophe
AU  - Bastin, Christine
TI  - Multimodal imaging of microstructural cerebral changes and loss of synaptic density in Alzheimer’s disease
AID  - 10.1101/2023.04.14.23288516
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.04.14.23288516
4099  - http://medrxiv.org/content/early/2023/04/17/2023.04.14.23288516.short
4100  - http://medrxiv.org/content/early/2023/04/17/2023.04.14.23288516.full
AB  - Multiple neuropathological changes are involved in Alzheimer’s disease (AD). AD hallmark biomarkers are amyloid-beta, tau pathology, and neuronal and synaptic loss. Other possible brain tissue-related biomarkers, such as iron and myelin content in the brain, are less frequently studied. Thanks to quantitative MRI (qMRI), tissue parameters such as magnetization transfer (MT), effective transverse relaxation (R2*), and proton density (PD) can be determined quantitatively, enabling the detection of microstructural tissue-related alterations in aging and neurodegenerative diseases. The current study investigated the co-occurrence of neurodegeneration (as measured with synaptic density), increased iron content, and decreased myelin content in Alzheimer’s disease. The study involved 24 amyloid-positive patients (AD, 11 males) and 19 healthy controls (HC, 9 males). All participants underwent a multi-parameter mapping MRI protocol, from which quantitative maps for MTsat and R2* were estimated. Synaptic density was indexed by the total volume distribution map (Vt) derived from [18F] UCB-H PET imaging. First, groups were compared with univariate statistical analyses applied to R2*, MTsat and Vt maps. Then multivariate General Linear Model (mGLM) was used to detect the co-occurrence of changes in R2*, MTsat, and Vt at the voxel level. Univariate GLM analysis of R2* showed no significant difference between the two groups. In contrast, the same analysis for MTsat resulted in a significant between-group difference in the right hippocampus at the cluster level with a corrected threshold (P-value < .05). The mGLM analysis revealed a significant difference in both right and left hippocampus between the AD and HC groups, as well as in the left precuneus, right middle frontal, and left superior orbitofrontal gyrus when all three modalities were present, suggesting these regions as the most affected despite the diverse changes of myelin, iron, and synapse degeneration in AD. Here, the mGLM is introduced as an alternative for multiple comparisons between different modalities, as it reduces the risk of false positives due to the multiplicity of the tests while informing about the co-occurrence of neuropathological processes in dementia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the ULiege Research Concerted Action (SLEEPDEM, grant 17/2109) and Walloon Region. [18F] Flutemetamol was provided by GE Healthcare. Christine Bastin is a Senior Research Associate at the F.R.S.-FNRS and Christophe Phillips is a Research Director at the F.R.S.-FNRS. (Fonds National de la Recherche Scientifique)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures performed in studies involving human participants were approved by the Ethics Committee of the Liege University Hospital (Belgium), reference number EudraCT 2014-000286-50, and were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.”I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors